Menu
Search
|

Menu

Close
X

XBiotech Inc XBIT.OQ (NASDAQ Stock Exchange Global Select Market)

4.27 USD
-- (--)
As of Jul 13
chart
Previous Close 4.27
Open --
Volume --
3m Avg Volume 34,954
Today’s High --
Today’s Low --
52 Week High 5.80
52 Week Low 3.55
Shares Outstanding (mil) 35.52
Market Capitalization (mil) 151.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.115
FY17
-0.975
FY16
-1.628
FY15
-1.214
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
2.69
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-38.43
13.23
Return on Equity (TTM)
vs sector
-38.44
15.28

EXECUTIVE LEADERSHIP

John Simard
Chairman of the Board, President, Chief Executive Officer, Founder, Since
Salary: $551,380.00
Bonus: --
Scott Whitehurst
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Kelly Thornburg
Senior Vice President - Operations, Since 2015
Salary: --
Bonus: --
Queena Han
Vice President - Finance, Human Resources, Since
Salary: --
Bonus: --
David Combs
Vice President - Manufacturing, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Building 4, 8201 E Riverside Dr
AUSTIN   TX   78744-1602

Phone: +1512.3862930
Site:

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

SPONSORED STORIES